Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$113.6 million.

  • Coherus Oncology's Net Cash Flow fell 8394.21% to -$113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 6729.5%. This contributed to the annual value of $22.9 million for FY2024, which is 4179.54% down from last year.
  • Coherus Oncology's Net Cash Flow amounted to -$113.6 million in Q3 2025, which was down 8394.21% from $134.5 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Net Cash Flow high stood at $156.9 million for Q1 2024, and its period low was -$281.7 million during Q1 2021.
  • Its 5-year average for Net Cash Flow is -$23.1 million, with a median of $7.4 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 188452.23% in 2021, then surged by 43096.49% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Net Cash Flow stood at $56.7 million in 2021, then plummeted by 494.07% to -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then rose by 25.03% to $28.3 million in 2024, then crashed by 501.33% to -$113.6 million in 2025.
  • Its last three reported values are -$113.6 million in Q3 2025, $134.5 million for Q2 2025, and -$43.6 million during Q1 2025.